

PRESS RELEASE



May 15 2019, Lund, Sweden

Immunovia to present at Jefferies 2019 Global Healthcare Conference in New York City, June 4-7 2019

LUND, SWEDEN — Immunovia AB (publ) (“Immunovia”) today announced that Mats Grahn, CEO, will present and host one-on-one investor meetings at the Jefferies 2019 Global Healthcare Conference in New York City.

Event Details:

Jefferies 2019 Global Healthcare Conference in New York City

Friday, June 7, 2019

Presentation at 9:30 a.m. ET (15:30 CEST)

A webcast of the presentation will be available via the following link:

<http://wsw.com/webcast/jeff118/immnov/>. The webcast will also be archived shortly afterwards under "Presentations" in the Investors section of the Company's website at www.immunovia.com and be available for approximately 90 days.

For more information, please contact:

Julie Silber

Investor Relations Director, Immunovia

Tel.: +46-79-3486277

Email: julie.silber@immunovia.com

About Jefferies Group

Jefferies is a diversified financial services company engaged in investment banking and capital markets, asset management and direct investing. Jefferies Group offers a full range of investment banking, equities, fixed income, asset and wealth management products and services.

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###